Clinical Trials Directory

Trials / Completed

CompletedNCT02338323

Compare the Renal Protective Effects of Febuxostat and Benzbromarone

Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
160 (actual)
Sponsor
Shanghai 10th People's Hospital · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function, and which one could be better.

Detailed description

Chronic kidney disease patients with hyperuricemia and glomerular filtration rate (GFR) 20-50 ml/min were treated by febuxostat or benzbromarone. Follow up the changes of serum uric acid, serum creatinine and GFR levels. Compare the effects on renal function of these two drugs.

Conditions

Interventions

TypeNameDescription
DRUGFebuxostatIt acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
DRUGBenzbromaroneIt is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase

Timeline

Start date
2015-01-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2015-01-14
Last updated
2019-07-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02338323. Inclusion in this directory is not an endorsement.